Samsung Bioepis, G2GBio partner on long-acting obesity drug development
--------------------------------------------------------------------
Source: The Korea Herald
Published: 2026-03-16 18:12 UTC+10:00
Section: All News
Factuality Score: 100
Opinion Category: Neutral
Topics: Science, Health, Property, South Korea, Drugs, World News, Business & Economy
--------------------------------------------------------------------
Snippet:
Samsung Bioepis and Epis NexLab, subsidiaries of Samsung Epis Holdings, have signed a joint research and licensing agreement with Korean biotech G2GBio to develop long-acting obesity treatments, the companies said Monday.
--------------------------------------------------------------------